WINTOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
WINDTREE THERAPEUTICS INC /DE/
Financials through Q3 FY2025, quarter ended Sep 30, 2025Last filing: 10-Q on Nov 19, 2025
$0.00+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $26.68K
- P/E (TTM)
- –
- Dividend yield
- –
WINDTREE THERAPEUTICS INC /DE/ revenue by segment
By business segment
By product or service
| Revenue | FY2019 | FY2018 | FY2017 | % of revenue | YoY |
|---|---|---|---|---|---|
| License [Member] | $198.00K | $1.02M | $102.00K | 100.0% | -80.6% |
| Grant [Member] | – | $765.00K | – | – | – |
By region
From the segment and revenue-disaggregation notes of Windtree Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.